Acute erythroid leukemias are characterized by a predominantly erythroid population of bone marrow cells. Most authors agree that two main subtypes exist: (1) erythroleukemia (erythroid/myeloid) or acute myeloid leukemia (AML) M6a, according to the French-American-British criteria, 1, 2 in which 450% erythroid precursors in the entire nucleated cell population and 420% myeloblasts in the non-erythroid cell population are found, and (2) pure erythroid leukemia or AML M6b, according to the French-American-British classification, 1, 2 in which erythroblasts constitute more than 80% of the bone marrow cells with no significant myeloblastic component. [1] [2] [3] Whereas erythroleukemia (erythroid/myeloid) is predominantly a disease of adults and comprises 5-6% of all cases of AML, 4 pure erythroid leukemia is extremely rare, is usually associated with a rapid clinical course and can occur in all age groups. 5 The Mitelman database of chromosome aberrations and gene fusions in cancer provides karyotypic information on about 600 cases of acute erythroid leukemia. 6 The most common aberrations are structural and numerical changes of chromosomes 5 and 7, followed by trisomy 8. These aberrations are common also in other AML subtypes, 7 however, and indeed it seems that no specific chromosomal aberration or pathogenetic mechanism (for example, fusion gene or gene deregulation) leading to erythroid leukemia has been reported.
A 15-month-old boy was admitted to the local hospital with a history of failure to thrive, prolonged diarrhea, vomiting and high fever. A diagnosis of pure erythroid leukemia (AML M6b; Figure 1 ) was made and treatment was begun according to the NOPHO-AML 2004 protocol (Nordic Society of Pediatric Hematology and Oncology), 8 but the patient died of resistant disease after 5 months.
The G-banding analysis of short-term cultured bone marrow cells revealed an abnormal karyotype interpreted as 46,XY,-der(1)t(1;1)(p31;q21),t(1;16)(p31;q24) [11] /46,XY [9] . Fluorescence in situ hybridization, using the CBFB Dual Color Break Apart Rearrangement probe, indicated no rearrangement of CBFB; hence, the found translocation could not be a variant of the known AML-associated inv(16) or t(16;16). A series of fluorescence in situ hybridization-experiments with probes derived from bacteria artificial chromosomes was performed to identify the exact breakpoints of the t(1;16)(p31;q24); these were found with clones RP11-430G17 (mapping to 1p31.3) and RP11-830F9 (mapping to 16q24.3; Figure 2 ). The fluorescence in situ hybridization findings led us to reinterpret the 1;16-rearrangement as an unbalanced translocation and the karyotype was revised as 46,XY,der(1)t(1;1)(p31;q21),del(1)(p11p31),der(16)t(1;16) (p31;q24) ( Figure 3) .
To identify the exact breakpoint on the der(16q), appropriate fosmid clones were selected inside the region chr16: 87 493 639-87 591 195 (16q24), as this was where the breakpoint lay based on bacteria artificial chromosomes data. Only one gene is present in this region, the core-binding factor, runtdomain, alpha subunit 2 translocated to 3 (CBFA2T3, previously known as MTG16, myeloid translocation gene). The breakpoint on chromosome 16 was identified inside the big intron 1 of the CBFA2T3 gene. CBFA2T3 encodes a protein in the myeloid translocation gene family of transcriptional co-repressors. Recombination of CBFA2T3 with the RUNX1 gene has been demonstrated in six cases of AML with a t(16;21)(q24;q22) 9 and then with the CBFA2T3 breakpoint either between exons 1 and 2 or between exons 3 and 4. The fusion retains four evolutionarily conserved motifs, that is, NHR1, NHR2, NHR3 and the zinc finger domain NHF4. 9 In our case, the breakpoint was in intron 1, thus making the product of the rearrangement similar to that previously described.
To find out which gene was involved from chromosome 1, we selected three fosmid clones inside the chromosomal region chr1:61 917 304-62 051 594 (1p31.3), as this was where the breakpoint position had been found using bacteria artificial chromosomes clones. Two genes are present here, TM2D1 (betaamyloid binding protein precursor) and INADL (InaD-like). Fluorescence in situ hybridization experiments using the clone G248P88729H1 showed a specific hybridization signal on der(1)t(1;1), whereas clones G248P86539D6 and G248P8780H2 gave no signal in the abnormal metaphases, but a specific signal on 1p in the normal metaphases of the case; we therefore assume that the genomic regions corresponding to these fosmids were deleted in the unbalanced 1;16-rearrangement. The two genes of primary interest as they are localized closest to the breakpoint, TM2D1 and INADL, were found deleted partially or completely. The resolution level of fosmid clones does not allow us to determine the position of the breakpoint with precision, but the INADL gene had lost its 3 0 end, whereas the 5 0 end was still present on the der(1)t(1;1). A large part of TM2D1 was also lost through the rearrangements, but it is possible that sequences near the 5 0 and 3 0 end of this gene are still present on der(1)t(1;1) and/or t(1;16). INADL encodes a protein with multiple PDZ domains, which mediate protein-protein interactions, and proteins with multiple PDZ domains often organize multimeric complexes at the plasma membrane. The INADL protein localizes to tight junctions and to the apical membrane of epithelial cells. 10 The TM2D1 gene encodes a b-amyloid peptide-binding protein. 11 It contains a structural module related to that of the seven transmembrane domain G protein-coupled receptor superfamily known to be important in heterotrimeric G protein activation (UCSC Genome Browser at http://genome. ucsc.edu/cgi-bin/).
Unfortunately, RNA obtained from leukemic blood was heavily degraded and could not be used for reverse transcription PCR or rapid amplification of cDNA ends studies, something that would have been necessary to determine the molecular consequences of the karyotypic alterations. However, two main putative leukemogenic mechanisms can be envisaged in view of the findings described above. The first is that a fusion gene with CBF2T3 as its 3 0 moiety might have been generated by the 1;16-translocation. The fact that CBFA2T3 is known to operate via a fusion gene mechanism in other types of AML 9 and then showing a similar breakpoint position (between exons 1 and 2)
to that of our case, adds to the attraction of this hypothesis. The two candidate partners of CBFA2T3 in such fusion would be INADL and TM2D1. None of them is known to participate in leukemogenesis in any other gene fusion or, for that matter, in any other way. The second mechanism that our findings indicate could be operative in the present case, is loss of tumor suppressor activity from the region of 1p shown to be homozygously deleted. This region contains four genes: TM2D1, INADL, L1TD1 (Line-1 type transposase domain containing 1) and KANK4 (ankyrin repeat domain 38). Although the first two genes may be partially deleted and, therefore, also potentially could be fused with CBFA2T3 on 16q, the last two are lost completely. L1TD1 belongs to the transposase 22 family and the only information about it presently available is that LINE-1 hypomethylation is associated with increased CpG island methylation in Helicobacter pylori-related enlarged-fold gastritis.
12 KANK4 is one of the genes encoding the Kank family of proteins which are characterized by their unique structure, coiled-coil motif in the N-terminal region and ankyrin-repeats in the C-terminal region, with an additional motif, KN, at the N-terminus. 13 Whereas the human Kank1 gene (KANK1) was found as a candidate tumor suppressor gene for renal cell carcinoma mapping to chromosome band 9p24, the other members were discovered on the basis of domain and phylogenetic analyses. Deletions of the KANK1 locus have been reported in renal cell carcinoma, cervical carcinoma, bladder cancer, hepatocellular carcinoma, pancreatic carcinoma, lung cancer, acute lymphocytic leukemia and breast cancer. We found another member of the Kank family, KANK4, homozygously deleted in our case. Whether this deletion was pathogenetically important, remains unknown.
Regardless of which genes are pathogenetically involved in the t(1;16)(p31;q24), and also regardless of whether the important outcome is the generation of a leukemogenic fusion gene (the hypothesis we favor) or something else, it seems beyond any reasonable doubt that the 1;16-translocation is specific for acute erythroid leukemia. A search of the Mitelman database shows that a 1;16-rearrangement was found in five cases, 6 and in two of these a t(1;16)(p31;q24) was reported, that is, the very same translocation found in our patient. Kö ller This hybridization was performed using locusspecific probes derived from bacteria artificial chromosomes clones CTD-3010L24 (labeled in green), RP11-830F9 (labeled in blue), CTD-2555A7 (labeled in red) and RP11-1122C1 (labeled in yellow), all mapping to 16q24. Although the clones labeled in blue and green are hybridizing to the normal 16 and the der(16)t(1;16), the clones labeled in red and yellow hybridize only to the normal 16, indicating that the clones are missing from the rearranged chromosome, that is, the deletion starts (the breakpoint is located) between clones RP11-830F9 (labeled in blue) and CTD-2555A7 (labeled in red). (b) This hybridization was performed using bacteria artificial chromosomes clones RP11-430G17 (labeled in red), RP11-446E24 (labeled in green) and CTD-3251C12 (labeled in yellow) mapping to 1p32.3-1p33 and hybridizing only to the der(16)t (1;16) ; the clones proximal to RP11-430G17 were deleted, that is, the breakpoint on chromosome 1 is near or inside clone RP11-430G17. (c) This hybridization was performed using bacteria artificial chromosomes clones RP11-230B22 (labeled in yellow), RP11-434H24 (labeled in green) and RP11-746E15 (labeled in red), all mapping to 1p31.3 and hybridizing only to the der(1)t(1;1), that is, the last clones present in the rearrangement before the homozygous deletion. Figure 3 Partial karyotype of the der(1)t(1;1)(p31;q21), del(1) (p11p31) and der(16)t(1;16) found in the described case. G-banded chromosomes are presented on the left, whereas ideograms of the rearranged chromosomes are shown to the right. Arrows point at breakpoint positions.
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14 reported a 10-year-old child with acute erythroid leukemia and the karyotype 47,XY,t(1;16)(p31;q2?2),del(7) (q31), þ 19,del(20)(p11). Castaneda et al. 15 reported a 6-yearold child with an acute undifferentiated leukemia, but where the leukemic cells demonstrated an early erythroid lineage differentiation. The abnormal karyotype found at diagnosis and relapse was 51,XY,t(1;16)(p31;q24), þ 6, þ 10, þ 15, þ 19, þ 21. The present case is therefore the third of only three with a karyotype containing a t(1;16)(p31;q24), and all of them seem to have been the highly uncommon AML M6. Whether the association is even more distinct to pure erythroid leukemia (AML M6b) as in our patient, or only to acute erythroid leukemias in general, cannot be assessed on the basis of the low number of patients hitherto described.
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ZRF4, a combi-molecule with increased efficacy as compared with the individual components in chronic lymphocytic leukemia lymphocytes in vitro B-cell chronic lymphocytic leukemia (CLL) is characterized by actively dividing B-lymphocytes in the lymph nodes and bone marrow, as well as the accumulation of quiescent lymphocytes in the peripheral blood of affected patients. During treatment, the enzyme-mediated repair of DNA damage can induce resistance to chemotherapeutic drugs. 1 Even if combinations of chemotherapy with immunotherapy have shown higher response rates and longer duration of responses, they can be associated with poor tolerability characterized by deterioration of immune functions leading to infections. 2 More recently, bendamustine, a hybrid agent with a nitrogen mustard moiety and a purine analog, has been tested in clinical trials in CLL, demonstrating that hybrid molecules can result in increased therapeutic efficacy as compared with the nitrogen mustard analog alone. 3 We have previously demonstrated that imatinib,
